New York lawmakers are actively considering the legalization of psilocybin, the psychoactive compound found in certain mushrooms, for medicinal purposes. This move could position New York as the third state in the U.S., following Oregon and Colorado, to authorize psilocybin use for therapeutic applications.
Legislative Developments
Assembly Bill A628, introduced in the 2025 legislative session, seeks to legalize the adult possession and use of natural plant or fungus-based hallucinogens, including psilocybin. The bill outlines provisions for the cultivation, distribution, and use of these substances, aiming to establish a regulated framework for their medicinal application NYSenate.gov.
Additionally, Senate Bill 495 proposes the legalization of psilocybin therapy under stringent conditions. This legislation would permit psilocybin-assisted therapy in clinical settings or at home, administered by certified facilitators who have completed state-regulated training. The Department of Health would oversee the program, ensuring compliance with research, evaluation, and reporting standards.
Public Hearing Highlights
On September 30, 2025, the New York State Assembly Health Committee convened its first public hearing to explore the potential benefits and risks of psilocybin as a therapeutic agent. The session featured testimonies from medical professionals, researchers, and individuals who have experienced therapeutic benefits from psilocybin use. Notably, Joseph McKay, a retired New York City firefighter and 9/11 first responder, shared how psilocybin alleviated his chronic cluster headaches and post-traumatic stress disorder, conditions that had previously been resistant to conventional treatments.
These personal accounts underscore the growing interest in psilocybin as a viable treatment option for various mental health conditions. However, experts have cautioned that while initial findings are promising, further research is necessary to fully understand the long-term effects and efficacy of psilocybin therapy.
Federal Considerations
Despite its Schedule I classification under federal law, which denotes substances with no currently accepted medical use and a high potential for abuse, psilocybin has garnered attention from federal agencies. In 2018 and 2019, the U.S. Food and Drug Administration granted “breakthrough therapy” designation to psilocybin for treatment-resistant depression, facilitating expedited clinical trials. Additionally, the FDA issued draft guidance in 2023 to support psilocybin research, indicating a federal acknowledgment of its potential therapeutic benefits.
Looking Ahead
As New York continues to deliberate on psilocybin legalization, the outcome could significantly influence national perspectives on psychedelic substances in medical treatment. The state’s approach to regulation and implementation will likely serve as a model for other jurisdictions considering similar measures. Lawmakers are expected to reconvene in 2026 to further discuss and potentially advance psilocybin legislation, with the aim of providing patients access to alternative therapeutic options under regulated conditions.
Dabbin-Dad Newsroom
